erbB-2 (HER-2) and breast cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The erbB-2 gene (also known as HER2) plays a crucial role in cell growth and is a target for breast cancer therapies.
• Understanding alterations in erbB-2 status from primary to recurrent or metastatic disease is vital for effective treatment strategies.

Purpose of the Study:

• To investigate and compare erbB-2 gene and protein alterations in primary breast tumors versus matched recurrent or metastatic lesions.
• To assess the concordance of erbB-2 status between primary and advanced disease stages.

Main Methods:

• Examined primary invasive breast cancers and subsequent metastases from 113 patients.
• Evaluated erbB-2 expression via immunohistochemistry using multiple reagents (CB11, TAB 250, DAKO anti-erbB-2, HercepTest).
• Assessed erbB-2 gene copy number using fluorescence in situ hybridization (FISH).

Main Results:

• High correlation was observed between different immunohistochemical reagents for erbB-2 detection.
• Generally good concordance (average 82%) between immunohistochemistry and FISH for erbB-2 status.
• Approximately 80% of patients showed similar erbB-2 expression and gene copy number in primary and metastatic tissues.
• Discordance was noted in about 20% of cases, often involving a normal primary tumor with altered metastases.
• erbB-2 discordance, specifically with CB11 staining, was linked to patient survival outcomes.

Conclusions:

• While erbB-2 status is largely consistent between primary and metastatic breast cancer, a significant minority of cases exhibit discordance.
• This discordance may arise from clonal selection or genetic drift.
• The association of discordance with survival highlights the clinical relevance of monitoring erbB-2 status throughout disease progression.